MAXON
20.4.2022 18:10:09 CEST | Business Wire | Press release
Maxon , the developers of professional software solutions for editors, filmmakers, motion designers and visual effects artists, today announced that all Maxon products are now included in its value-packed subscription: Cinema 4D, Redshift, Red Giant, Universe, Forger and now ZBrush, acquired in December of last year, are all included in Maxon One for the same affordable price. Additionally, Maxon unveiled its Spring 2022 product upgrades that include an incredible set of new features and enhancements. This multi-product, feature-rich update once again illustrates Maxon’s commitment to delivering consistent product development and superior value to the Maxon One offering.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220420005268/en/
“Our goal is to provide artists with trailblazing technology and workflows to create in all dimensions,” said David McGavran, Maxon CEO. “This expansive update across all of Maxon’s creative tools comes together to provide incredible value and opportunities for creative expression in Maxon One.”
See Maxon One in Action at NAB 2022 and on The 3D and Motion Design Show
Maxon will be hosting exclusive presentations from industry-leading artists in its Booth (#N5920) at NAB 2022, April 24-27, 2022. For those unable to attend the show, the presentations will be streaming simultaneously at 3DMotionShow.com .
Exciting new enhancements and upgrades to Maxon One products include:
Cinema 4D S26: Significant emphasis has been put on unifying workflows with the best technology from around the Maxon family – the additions of Redshift CPU and ZBrush’s automatic retopology tools. Cinema 4D Subscription Release 26 also includes great enhancements across the entire 3D workflow - Modeling, Animation, Simulation, Rendering.
Redshift: Redshift is Everywhere. With the initial release of Redshift CPU, users can make use of Redshift’s powerful materials and rendering on any system and a growing number of creative tools including Houdini, Maya, 3ds max, Blender, Katana, Vectorworks and Archicad. The new Redshift Standard material is easy to use and offers diverse shading models for improved photorealism.
Red Giant:
- VFX Suite 3 introduces Real Lens Flares based on simulated optical models and ray traced light. This technology preview will evolve with the participation of our artistic community.
- Magic Bullet Suite 16 adds new Halation and Optical Diffusion tools for Looks, along with OpenColorIO support.
- Trapcode Suite 18 now offers M1 support for all Trapcode tools, and layer maps support in Particular.
Universe: Universe 6 adds exciting new tools providing many new options to be creative and enhance an artist’s workflow. Sketchify adds sketch- and toon-like effects to footage, ChromaTown creates chromatic streaks and blurs for warpy looks and transitions, Box Bokeh provides square or diamond shaped lens bokeh effects, and Stretch Transition adds a stretchy crossfade between clips for a warp-like transition. Combined with over 70 new presets, Universe 6 helps artists to get impressive results quickly in a fun and intuitive way.
Forger: The latest version of Forger reveals the first stage in Maxon’s plan to provide powerful hard-surface modeling capabilities to 3D artists. Built with Cinema 4D’s polygonal foundation, Forger now offers a selection of polygonal primitives: planes, cubes, spheres, cylinders, torus, pyramids, capsules, oil tanks, etc.
Maxon One subscribers can immediately download all product updates via Maxon App. Everyone can download a 14-day trial of the entire Maxon One offering from within Maxon App and experience for themselves all the great new features across the entire Maxon family of products.
More Details at maxon.net
About Maxon
Maxon makes powerful, yet approachable software solutions for content creators working in 2D and 3D design, motion graphics, visual effects and visualization. Maxon’s innovative product portfolio helps artists supercharge their creative workflows. Our product lines include the award-winning Cinema 4D suite of 3D modeling, simulation and animation technology; the creativity-on-the-go Forger mobile sculpting app; the diverse Red Giant lineup of revolutionary editing, motion design and filmmaking tools; the leading-edge, blazingly fast Redshift renderer; and ZBrush , the industry-standard digital sculpting and painting solution.
Maxon’s team is comprised of fun, passionate people who believe in building and empowering a successful artistic community. From our popular, inclusive events to our free Cineversity educational resources, Maxon recognizes that developing strong connections with creatives and fostering their professional growth is integral to our ability to stay on top of industry trends and better serve customers.
Maxon is part of the Nemetschek Group .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220420005268/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom